(Q35770177)

10 August 2017

1 reference

title

Development of novel targeted therapies in the treatment of malignant glioma (English)

1 reference

10 August 2017

2

Darell D Bigner

1 reference

10 August 2017

1

Jeremy N Rich

1 reference

10 August 2017

publication date

1 May 2004

1 reference

Nature Reviews Drug Discovery

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

5

1 reference

10 August 2017

page(s)

430-446

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1380

10 August 2017

exact match

0 references

cites work

Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma.

1 reference

Infrequent methylation of CDKN2A(MTS1/p16) and rare mutation of both CDKN2A and CDKN2B(MTS2/p15) in primary astrocytic tumours

21 January 2018

1 reference

Expression of three viral oncogenes (v-sis, v-myc, v-fos) in primary human brain tumors of neuroectodermal origin

21 January 2018

1 reference

Interstitial fluid pressure in intracranial tumours in patients and in rodents

21 January 2018

1 reference

Platelet-derived growth factor signaling and human cancer

21 January 2018

1 reference

Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells

21 January 2018

1 reference

RESPONSE: Re: Brain and Other Central Nervous System Cancers: Recent Trends in Incidence and Mortality

21 January 2018

1 reference

Epidemiology of primary brain tumors: current concepts and review of the literature

31 March 2020

1 reference

Tumors of the brain and nervous system after radiotherapy in childhood

31 March 2020

1 reference

Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications

31 March 2020

1 reference

Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis

31 March 2020

1 reference

Prognostic factors for survival in adult patients with cerebral low-grade glioma.

31 March 2020

1 reference

Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome

31 March 2020

1 reference

Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group stud

31 March 2020

1 reference

Phase II trial of temozolomide in patients with progressive low-grade glioma

31 March 2020

1 reference

Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06.

31 March 2020

1 reference

Primary brain tumours in adults.

31 March 2020

1 reference

Extent of resection in malignant gliomas: a critical summary.

31 March 2020

1 reference

Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials

31 March 2020

1 reference

Long-term survivors of glioblastoma: statistical aberration or important unrecognized molecular subtype?

31 March 2020

1 reference

Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.

31 March 2020

1 reference

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

31 March 2020

1 reference

31 March 2020

The Hallmarks of Cancer

1 reference

Subsets of glioblastoma multiforme defined by molecular genetic analysis.

31 March 2020

1 reference

p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression.

31 March 2020

1 reference

31 March 2020

Surfing the p53 network

1 reference

Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms

31 March 2020

1 reference

Clonal expansion of p53 mutant cells is associated with brain tumour progression

31 March 2020

1 reference

Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas

31 March 2020

1 reference

The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation

31 March 2020

1 reference

Regulation of p53 stability by Mdm2

31 March 2020

1 reference

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest

31 March 2020

1 reference

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53

31 March 2020

1 reference

Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.

31 March 2020

1 reference

p14ARF deletion and methylation in genetic pathways to glioblastomas.

31 March 2020

1 reference

Incidence of p14ARF gene deletion in high-grade adult and pediatric astrocytomas.

31 March 2020

1 reference

p53 gene mutation and ink4a-arf deletion appear to be two mutually exclusive events in human glioblastoma.

31 March 2020

1 reference

31 March 2020

1 reference

Alterations of cell cycle regulatory genes in primary (de novo) and secondary glioblastomas.

31 March 2020

1 reference

Mitogenic signaling cascades in glial tumors

31 March 2020

1 reference

Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

31 March 2020

1 reference

Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

31 March 2020

1 reference

Scatter factor expression and regulation in human glial tumors

31 March 2020

1 reference

Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

31 March 2020

1 reference

Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

31 March 2020

1 reference

Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma.

31 March 2020

1 reference

Targeting RAS signalling pathways in cancer therapy

31 March 2020

1 reference

Proliferation of human malignant astrocytomas is dependent on Ras activation.

31 March 2020

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

31 March 2020

1 reference

PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer

31 March 2020

1 reference

Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers

31 March 2020

1 reference

P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase

31 March 2020

1 reference

Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN

31 March 2020

1 reference

The lipid phosphatase activity of PTEN is critical for its tumor supressor function

31 March 2020

1 reference

The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway

31 March 2020

1 reference

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

31 March 2020

1 reference

Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN.

31 March 2020

1 reference

Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas

31 March 2020

1 reference

Analysis of proliferation and apoptosis in brain gliomas: prognostic and clinical value

31 March 2020

1 reference

Chemosensitivity of human malignant glioma: modulation by p53 gene transfer

31 March 2020

1 reference

Transfection of C6 glioma cells with the bax gene and increased sensitivity to treatment with cytosine arabinoside

31 March 2020

1 reference

Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.

31 March 2020

1 reference

THE LIMITED IN VITRO LIFETIME OF HUMAN DIPLOID CELL STRAINS

31 March 2020

1 reference

Role of Telomeres and Telomerase in the Pathogenesis of Human Cancer

31 March 2020

1 reference

The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats

31 March 2020

1 reference

hEST2, the putative human telomerase catalytic subunit gene, is up-regulated in tumor cells and during immortalization

31 March 2020

1 reference

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

31 March 2020

1 reference

Telomerase activity in human brain tumours.

31 March 2020

1 reference

Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme.

31 March 2020

1 reference

A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice

31 March 2020

1 reference

Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice

31 March 2020

1 reference

PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo

31 March 2020

1 reference

Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation.

31 March 2020

1 reference

Epidermal growth factor receptor and Ink4a/Arf

31 March 2020

1 reference

Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects

31 March 2020

1 reference

Mouse tumor model for neurofibromatosis type 1

31 March 2020

1 reference

Vascular-specific growth factors and blood vessel formation

31 March 2020

1 reference

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

31 March 2020

1 reference

Drug delivery to tumors of the central nervous system

31 March 2020

1 reference

Measurement of blood-brain barrier permeability in a tumor model using magnetic resonance imaging with gadolinium-DTPA

31 March 2020

1 reference

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.

31 March 2020

1 reference

Intracarotid low dose bradykinin infusion selectively increases tumor permeability through activation of bradykinin B2 receptors in malignant gliomas.

31 March 2020

1 reference

Convection-enhanced delivery of macromolecules in the brain

31 March 2020

1 reference

Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas

31 March 2020

1 reference

Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malig

31 March 2020

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

31 March 2020

1 reference

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor

31 March 2020

1 reference

Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR

31 March 2020

1 reference

Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum

31 March 2020

1 reference

Dynamic contrast-enhanced magnetic resonance imaging as a surrogate marker of tumor response to anti-angiogenic therapy in a xenograft model of glioblastoma multiforme

31 March 2020

1 reference

Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants. NABTT CNS Consortium. The New Approaches to Brain Tumor Therapy.

31 March 2020

1 reference

31 March 2020

1 reference

ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial

31 March 2020

1 reference

Cancer revoked: oncogenes as therapeutic targets

31 March 2020

1 reference

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification

31 March 2020

1 reference

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

31 March 2020

1 reference

The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling

31 March 2020

1 reference

Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology

31 March 2020

1 reference

A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity

31 March 2020

1 reference

Prognostic applications of the epidermal growth factor receptor and its ligand, transforming growth factor-alpha

31 March 2020

1 reference

Effect of tyrphostin on cell growth and tyrosine kinase activity of epidermal growth factor receptor in human gliomas

31 March 2020

1 reference

Phase II trial of gefitinib in recurrent glioblastoma

31 March 2020

1 reference

Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors

31 March 2020

1 reference

Toxicity, efficacy, and pharmacology of suramin in adults with recurrent high-grade gliomas

31 March 2020

1 reference

Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line

31 March 2020

1 reference

Opinion: Searching for the elusive targets of farnesyltransferase inhibitors

31 March 2020

1 reference

Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor

31 March 2020

1 reference

Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth

31 March 2020

1 reference

Integration of Growth Factor and Nutrient Signaling

31 March 2020

1 reference

Identification of TOR signaling complexes: more TORC for the cell growth engine

31 March 2020

1 reference

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

31 March 2020

1 reference

Human brain tumor xenografts in nude mice as a chemotherapy model.

31 March 2020

1 reference

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

31 March 2020

1 reference

The role of transforming growth factor-beta in primary brain tumors

31 March 2020

1 reference

Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy

31 March 2020

1 reference

Transforming growth factor-beta-mediated p15(INK4B) induction and growth inhibition in astrocytes is SMAD3-dependent and a pathway prominently altered in human glioma cell lines

31 March 2020

1 reference

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

31 March 2020

1 reference

Inhibition of phosphatidylinositol 3-kinase signaling negates the growth advantage imparted by a mutant epidermal growth factor receptor on human glioblastoma cells

31 March 2020

1 reference

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

31 March 2020

1 reference

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

31 March 2020

1 reference

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

31 March 2020

1 reference

Advances in Molecular Therapies in Patients with Brain Tumors

31 March 2020

1 reference

Genetic and signaling pathway alterations in glioblastoma relevance to novel targeted therapies

31 March 2020

1 reference

Targeted molecular therapy of GBM.

31 March 2020

1 reference

Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and Ras signaling pathways

31 March 2020

1 reference

Genetically engineered mouse models of astrocytoma: GEMs in the rough?

31 March 2020

1 reference

Preirradiation osmotic blood-brain barrier disruption plus combination chemotherapy in gliomas: quantitation of tumor response to assess chemosensitivity.

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Integration of growth factor and nutrient signaling: implications for cancer biology

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1380

1 reference

10 August 2017

1 reference